Researchers are making progress in the development of CDK2 inhibitors for cancer therapy, with studies focusing on the synthesis and biological evaluation of various compounds. Different classes of molecules, including imidazo[1,2-a]pyridine derivatives, pyrimidine-sulfonamide hybrids, and 2-thiohydantoin analogues, are being investigated for their potential as anticancer agents. The therapeutic potential of these compounds is being explored through various methods, including molecular docking, molecular dynamics investigations, and biological evaluations.